AGR2 and esophageal squamous cell carcinoma: Further research has confirmed that AGR2 can be overexpressed and exert pro-cancer functions in various solid cancers [24], ranging from adenocarcinomas to squamous carcinomas, including breast adenocarcinomas [87], pancreatic adenocarcinomas [88], esophageal adenocarcinomas [89], prostate adenocarcinomas [78], esophageal squamous cell carcinomas [90], and HCC [12].